Dr. Atli Thorarensen is a Research Fellow at Pfizer and is currently a member of the Inflammation and Immunology Leadership team. For the past 21 years with Pfizer he has directly managed a group reporting to him ranging from 0-7 individuals and a significantly more valuable experience is his project management experience where he has managed in the context of chemistry POC to current role of RPL several large multidisciplinary teams of line representatives from toxicology, molecular sciences, pharmacology, structural biology, pharmaceutical sciences and pharmacokinetics / dynamics groups, computational chemistry, and medicinal chemistry. His therapeutic experience includes inflammation and immunology, allergy and respiratory, cardiovascular pain and antibacterial/ anti-viral domain. His drug hunter expertise includes an in depth understanding of all aspects of drug discovery including drug discovery, chemical biology, biology (especially enzymology), computational chemistry, ADME and toxicology. This is illustrated by the broadness of his publications and by his internal awards: 2007 PGRD Achievement Award winner for leading and contributions to the HPGDS project and 2017 Team Achievement Awards for JAK3. He has also delivered multiple projects from early portfolio entry into clinical candidate nomination. A highlighted example is the JAK3 inhibitor PF-06651600 now in phase 3 clinical trials. He received his Post-doctorate from University of Uppsala and Ph.D from University of Illinois at Urbana-Champaign, USA.
NSTL
